Literature DB >> 28494969

Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance.

Martin Aguilar1, Jianlin Feng2, Edward Vigmond3, Philippe Comtois1, Stanley Nattel4.   

Abstract

The atrial-specific ultrarapid delayed rectifier K+ current (IKur) inactivates slowly but completely at depolarized voltages. The consequences for IKur rate-dependence have not been analyzed in detail and currently available mathematical action-potential (AP) models do not take into account experimentally observed IKur inactivation dynamics. Here, we developed an updated formulation of IKur inactivation that accurately reproduces time-, voltage-, and frequency-dependent inactivation. We then modified the human atrial cardiomyocyte Courtemanche AP model to incorporate realistic IKur inactivation properties. Despite markedly different inactivation dynamics, there was no difference in AP parameters across a wide range of stimulation frequencies between the original and updated models. Using the updated model, we showed that, under physiological stimulation conditions, IKur does not inactivate significantly even at high atrial rates because the transmembrane potential spends little time at voltages associated with inactivation. Thus, channel dynamics are determined principally by activation kinetics. IKur magnitude decreases at higher rates because of AP changes that reduce IKur activation. Nevertheless, the relative contribution of IKur to AP repolarization increases at higher frequencies because of reduced activation of the rapid delayed-rectifier current IKr. Consequently, IKur block produces dose-dependent termination of simulated atrial fibrillation (AF) in the absence of AF-induced electrical remodeling. The inclusion of AF-related ionic remodeling stabilizes simulated AF and greatly reduces the predicted antiarrhythmic efficacy of IKur block. Our results explain a range of experimental observations, including recently reported positive rate-dependent IKur-blocking effects on human atrial APs, and provide insights relevant to the potential value of IKur as an antiarrhythmic target for the treatment of AF.
Copyright © 2017 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28494969      PMCID: PMC5425383          DOI: 10.1016/j.bpj.2017.03.022

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  42 in total

1.  Modeling the effect of Kv1.5 block on the canine action potential.

Authors:  Joachim Almquist; Mikael Wallman; Ingemar Jacobson; Mats Jirstrand
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

2.  Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes.

Authors:  G R Li; J Feng; Z Wang; B Fermini; S Nattel
Journal:  Circ Res       Date:  1996-05       Impact factor: 17.367

3.  Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation.

Authors:  Sandeep V Pandit; Omer Berenfeld; Justus M B Anumonwo; Roman M Zaritski; James Kneller; Stanley Nattel; José Jalife
Journal:  Biophys J       Date:  2005-03-25       Impact factor: 4.033

4.  The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy.

Authors:  Martin Aguilar; Stanley Nattel
Journal:  J Cardiovasc Pharmacol       Date:  2015-11       Impact factor: 3.105

5.  Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes.

Authors:  B Koidl; P Flaschberger; P Schaffer; B Pelzmann; E Bernhart; H Mächler; B Rigler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

6.  Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.

Authors:  Arne van Hunnik; Dennis H Lau; Stef Zeemering; Marion Kuiper; Sander Verheule; Ulrich Schotten
Journal:  Heart Rhythm       Date:  2015-12-08       Impact factor: 6.343

7.  Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation.

Authors:  Tao Yang; Ping Yang; Dan M Roden; Dawood Darbar
Journal:  Heart Rhythm       Date:  2010-06-01       Impact factor: 6.343

8.  Sequence and functional expression in Xenopus oocytes of a human insulinoma and islet potassium channel.

Authors:  L H Philipson; R E Hice; K Schaefer; J LaMendola; G I Bell; D J Nelson; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

9.  Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.

Authors:  John Ford; James Milnes; Erich Wettwer; Torsten Christ; Marc Rogers; Kathy Sutton; David Madge; Laszlo Virag; Norbert Jost; Zoltan Horvath; Klaus Matschke; Andras Varro; Ursula Ravens
Journal:  J Cardiovasc Pharmacol       Date:  2013-05       Impact factor: 3.105

10.  Comprehensive analyses of ventricular myocyte models identify targets exhibiting favorable rate dependence.

Authors:  Megan A Cummins; Pavan J Dalal; Marco Bugana; Stefano Severi; Eric A Sobie
Journal:  PLoS Comput Biol       Date:  2014-03-27       Impact factor: 4.475

View more
  11 in total

1.  Populations of in silico myocytes and tissues reveal synergy of multiatrial-predominant K+ -current block in atrial fibrillation.

Authors:  Haibo Ni; Alex Fogli Iseppe; Wayne R Giles; Sanjiv M Narayan; Henggui Zhang; Andrew G Edwards; Stefano Morotti; Eleonora Grandi
Journal:  Br J Pharmacol       Date:  2020-08-09       Impact factor: 8.739

Review 2.  The role of personalized atrial modeling in understanding atrial fibrillation mechanisms and improving treatment.

Authors:  Konstantinos N Aronis; Rheeda Ali; Natalia A Trayanova
Journal:  Int J Cardiol       Date:  2019-01-31       Impact factor: 4.164

3.  Revealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity.

Authors:  Nicholas Ellinwood; Dobromir Dobrev; Stefano Morotti; Eleonora Grandi
Journal:  Chaos       Date:  2017-09       Impact factor: 3.642

4.  Transient outward K+ current can strongly modulate action potential duration and initiate alternans in the human atrium.

Authors:  Haibo Ni; Henggui Zhang; Eleonora Grandi; Sanjiv M Narayan; Wayne R Giles
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-12-21       Impact factor: 4.733

5.  In Silico Assessment of Efficacy and Safety of IKur Inhibitors in Chronic Atrial Fibrillation: Role of Kinetics and State-Dependence of Drug Binding.

Authors:  Nicholas Ellinwood; Dobromir Dobrev; Stefano Morotti; Eleonora Grandi
Journal:  Front Pharmacol       Date:  2017-11-07       Impact factor: 5.810

Review 6.  Understanding AF Mechanisms Through Computational Modelling and Simulations.

Authors:  Konstantinos N Aronis; Rheeda L Ali; Jialiu A Liang; Shijie Zhou; Natalia A Trayanova
Journal:  Arrhythm Electrophysiol Rev       Date:  2019-07

7.  A Mathematical Model for Electrical Activity in Pig Atrial Tissue.

Authors:  Víctor Peris-Yagüe; Tony Rubio; Funsho E Fakuade; Niels Voigt; Stefan Luther; Rupamanjari Majumder
Journal:  Front Physiol       Date:  2022-03-10       Impact factor: 4.566

8.  Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.

Authors:  Haibo Ni; Dominic G Whittaker; Wei Wang; Wayne R Giles; Sanjiv M Narayan; Henggui Zhang
Journal:  Front Physiol       Date:  2017-11-23       Impact factor: 4.566

9.  Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation.

Authors:  Young M Kim; Robert Lakin; Hao Zhang; Jack Liu; Ayaaz Sachedina; Maneesh Singh; Emily Wilson; Marco Perez; Subodh Verma; Thomas Quertermous; Jeffrey Olgin; Peter H Backx; Euan A Ashley
Journal:  JCI Insight       Date:  2020-09-03

10.  Individual Contributions of Cardiac Ion Channels on Atrial Repolarization and Reentrant Waves: A Multiscale In-Silico Study.

Authors:  Henry Sutanto
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.